Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AE | Adverse event |
| AL | Activation loop |
| ALT | Alanine aminotransferase |
| AP | ATP-binding pocket |
| ASCO | American Society of Clinical Oncology |
| AST | Aspartate aminotransferase |
| ATP | Adenosine triphosphate |
| AUC | Area under the concentration-time curve |
| AUCss | Area under the concentration-time curve at steady state |
| BICR | Blinded independent central review |
| BTD | Breakthrough Therapy Designation |
| CAS | Chemical Abstracts Service |
| CBR | Clinical benefit rate |
| CI | Confidence interval |
| CR | Complete response |
| ctDNA | Circulating tumor DNA |
| CTOS | Connective Tissue Oncology Society |
| CYP3A4 | Cytochrome P450 3A4 |
| DLT | Dose-limiting toxicity |
| ECOG | Eastern Cooperative Oncology Group |
| FDA | U.S. Food and Drug Administration |
| GEIS | Spanish Group for Research on Sarcomas |
| GI | Gastrointestinal |
| GIST | Gastrointestinal stromal tumor |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| KIT | KIT receptor tyrosine kinase |
| mPFS | Median progression-free survival |
| mRECIST | Modified Response Evaluation Criteria in Solid Tumors |
| MTD | Maximum tolerated dose |
| mTOR | Mechanistic target of rapamycin |
| NCCN | National Comprehensive Cancer Network |
| NDA | New drug application |
| NTRK | Neurotrophic receptor tyrosine kinase |
| ORR | Objective response rate |
| OS | Overall survival |
| PD | Progressive disease |
| PDGFR | Platelet-derived growth factor receptor |
| PDGFRA | Platelet-derived growth factor receptor alpha |
| PDUFA | Prescription Drug User Fee Act |
| PFS | Progression-free survival |
| PK | Pharmacokinetics |
| PR | Partial response |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RP2D | Recommended phase 2 dose |
| RTOR | Real-Time Oncology Review |
| SCF | Stem cell factor |
| SCFR | Stem cell factor receptor |
| SD | Stable disease or standard deviation, according to context |
| TKI | Tyrosine kinase inhibitor |
| TRAE | Treatment-related adverse event |
| TRK | Tropomyosin receptor kinase |